STANÍK, Michal, Alexandr POPRACH, Michaela ZAPLETALOVÁ, Denisa KREJČÍ, Daniel MACIK, Ivo CAPAK, Jiří JARKOVSKÝ, Radek LAKOMY a Jan DOLEZEL. Comparison of Different Treatment Modalities Outcomes in Clinically Node-positive Bladder Cancer: Analysis of a Population-based Cancer Registry. CLINICAL GENITOURINARY CANCER. DALLAS: CIG MEDIA GROUP, LP, 2019, roč. 17, č. 4, s. "E759"-"E767", 9 s. ISSN 1558-7673. Dostupné z: https://dx.doi.org/10.1016/j.clgc.2019.04.007.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Comparison of Different Treatment Modalities Outcomes in Clinically Node-positive Bladder Cancer: Analysis of a Population-based Cancer Registry
Autoři STANÍK, Michal (703 Slovensko, garant), Alexandr POPRACH (203 Česká republika), Michaela ZAPLETALOVÁ (203 Česká republika, domácí), Denisa KREJČÍ (203 Česká republika, domácí), Daniel MACIK (203 Česká republika), Ivo CAPAK (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Radek LAKOMY (203 Česká republika) a Jan DOLEZEL (203 Česká republika).
Vydání CLINICAL GENITOURINARY CANCER, DALLAS, CIG MEDIA GROUP, LP, 2019, 1558-7673.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.695
Kód RIV RIV/00216224:14110/19:00111954
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.clgc.2019.04.007
UT WoS 000476618100006
Klíčová slova anglicky Chemotherapy; Combined modality therapy; Cystectomy; Lymphadenopathy; Urinary bladder neoplasms
Štítky 14119612, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 3. 1. 2020 12:10.
Anotace
Recently, a few retrospective studies demonstrated a potential benefit of multimodal therapy in patients with clinically node-positive bladder cancer. We assessed the efficacy of different treatment modalities in 661 patients (cTanyN1-3M0) identified from the Czech National Cancer Registry. When compared with chemotherapy, combined treatment integrating cystectomy and perioperative chemotherapy reduced the risk of overall mortality by 21% and may lead to a long-term survival in one-quarter of patients. Introduction: Patients with clinically node-positive bladder cancer were historically considered to have uniformly poor prognosis and were frequently treated with palliative chemotherapy (CHT) only. Although retrospective data show that long-term survival with combined treatment (surgery + CHT) is possible in one-third of these patients, consensus on a treatment algorithm is still lacking. The aim of the study is to compare the efficacy of different treatment modalities based on data from a population-based cancer registry. Patients and Methods: The study comprises 661 patients identified from the Czech National Cancer Registry (1996-2015) with cTanyN1-3M0 bladder cancer; 195 were treated with CHT alone, 234 underwent radical cystectomy alone (RC), and 232 received a combination of RC and perioperative CHT (RC + CHT). Multivariate Cox proportional hazard regression analyses were used to evaluate the effectiveness of various treatments. Results: The 5-year OS for CHT alone, RC alone, and RC + CHT were 21.7% (95% confidence interval [CI], 15.4%-28.0%), 12.1% (95% CI, 7.4%-16.7%), and 25.4% (95% CI, 18.9%-31.9%), respectively (P < .001). The median survivals were 17, 10, and 23 months, respectively. In multivariate analysis, age > 60 years (hazard ratio, 1.29; 95% CI, 1.06-1.56; P = .011) and clinical stage cT3-4 (hazard ratio, 1.39; 95% CI, 1.12-1.71; P = .002) were negative predictors of survival. When compared with CHT, RC + CHT reduced the risk of overall mortality by 21% (P = .044). Conclusion: Approximately one-quarter of clinically node-positive patients may achieve long-term survival with combined treatment integrating RC and perioperative CHT. The overall survival of patients is significantly improved with a multimodal approach in comparison to CHT alone. (C) 2019 Elsevier Inc. All rights reserved.
VytisknoutZobrazeno: 15. 5. 2024 03:42